tiprankstipranks
Trending News
More News >
Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
US Market

Nabriva Therapeutics (NBRVF) Income Statement

Compare
1,015 Followers

Nabriva Therapeutics Income Statement

Last quarter (Q2 2023), Nabriva Therapeutics's total revenue was $2.57M, a decrease of -70.67% from the same quarter last year. In Q2, Nabriva Therapeutics's net income was $-12.06M. See Nabriva Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 35.67M$ 27.22M$ 5.03M$ 7.75M$ 6.50M
Gross Profit
$ 7.09M$ 14.07M$ 3.44M$ 7.68M$ 6.50M
Operating Expenses
$ 62.58M$ 62.60M$ 69.57M$ 87.17M$ 120.88M
Depreciation and Amortization
$ 217.00K$ 637.00K$ 820.00K$ 770.00K$ 510.00K
EBITDA
$ -54.70M$ -47.42M$ -66.88M$ -78.72M$ -114.09M
Operating Income
$ -55.49M$ -48.53M$ -66.13M$ -79.49M$ -114.38M
Other Income/Expenses
$ -127.00K$ -432.00K$ -3.22M$ -3.17M$ -356.00K
Pretax Income
$ -55.62M$ -48.96M$ -69.34M$ -82.66M$ -114.73M
Net Income
$ -57.19M$ -49.45M$ -69.48M$ -82.76M$ -114.78M
Per Share Metrics
Basic EPS
$ -21.32$ -28.52$ -135.23$ -278.75$ -564.91
Diluted EPS
$ -21.32$ -28.52$ -135.23$ -278.75$ -564.91
Weighted Average Shares Outstanding
2.68M 1.73M 513.80K 296.80K 203.18K
Weighted Average Shares Outstanding (Diluted)
2.68M 1.73M 513.80K 296.80K 203.18K
Currency in USD

Nabriva Therapeutics Earnings and Revenue History